Business
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing. This agreement forms part of Polyrizon's ongoing efforts to advance its clinical development program, whic
About this update from Polyrizon Ltd.
[{"type":"text","content":"Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing.","length":393,"tagName":"p"},{"type":"text","content":"This agreement forms part of Polyrizon's ongoing efforts to advance its clinical development program, which also includes a recent manufacturing of GMP production of clinical trial material, successful completion of an FDA pre-submission meeting, and positive preclinical data demonstrating effective allergen-blocking performance.","length":335,"tagName":"p"},{"type":"text","content":"Under the agreement, the CRO will conduct a comprehensive package of preclinical biocompatibility studies in accordance with ISO 10993 standards and GLP requirements. The studies are expected to commence in the second quarter of 2026 and represent a key milestone in Polyrizon’s potential regulatory pathway toward initiating clinical trials, which are planned to commence later this year.","length":389,"tagName":"p"},{"type":"text","content":"The preclinical program includes cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity and pyrogenicity assessments, designed to support regulatory submissions and ensure product safety prior to human studies.","length":235,"tagName":"p"},{"type":"text","content":"“This agreement marks an important step in the advancement of our development program,” said Tomer Izraeli, CEO of Polyrizon. “We believe that engaging a globally recognized preclinical partner strengthens our regulatory strategy and supports our expected timeline toward initiating clinical trials later this year.”","length":316,"tagName":"p"},{"type":"text","content":"Polyrizon continues to execute its development roadmap as it advances its proprietary nasal medical device technology platform toward clinical validation.","length":154,"tagName":"p"},{"type":"text","content":"About Polyrizon","length":15,"tagName":"p"},{"type":"text","content":"Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form ...